Resumo
Purpose of review
Liver transplantation is the gold standard for the treatment of end-stage liver disease. No entanto, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, células-tronco hematopoéticas, bone marrow mononuclear cells, e células-tronco mesenquimais (MSC) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.
Recent findings
MSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. Adicionalmente, MSCs can be noninvasively isolated from various tissues and expandedex vivo in sufficient numbers for clinical evaluation.
Resumo
Atualmente, there is no approved MSC therapy for the treatment of liver disease. No entanto, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.
As informações desta página destinam-se a fins científicos, educacional, e fins informativos gerais. Abordagens clínicas, disponibilidade, e o status regulatório podem variar de acordo com o país, instituição, e indicação médica. Para decisões médicas individuais, os leitores devem consultar profissionais de saúde qualificados e centros médicos credenciados.
Este artigo foi elaborado pela equipe editorial da NBScience no âmbito da pesquisa clínica, biotecnologia, e informações médicas internacionais.
